Penitrium Bioscience Accelerates New Drug Development for Intractable Diseases

Research Focused on Applicability to Cancer and Autoimmune Diseases

Hyundai ADM Bio has changed its corporate name to 'Penitrium Bioscience' and is set to accelerate its new drug development strategy for the treatment of intractable diseases.

Penitrium Biosciences logo.

Hyundai ADM Bio announced on March 6 that it had changed its company name to Penitrium Bioscience at a regular shareholders' meeting. According to the company, the name change aims to clarify the research and development (R&D) strategy centered on 'Penitrium,' a new drug candidate currently under development.

Penitrium is an oral formulation drug based on niclosamide, an existing anthelmintic ingredient, with improved absorption in the body. It is being developed with the goal of a therapeutic approach that regulates cellular energy metabolism balance.

The company explained, "Our research focuses on whether this approach could evolve into a platform-type new drug that can be applied to various intractable diseases in the future, such as cancer and autoimmune disorders."

Penitrium Bioscience is currently preparing clinical trials for prostate cancer at the request of Hyundai Bioscience and for terminal breast and lung cancer patients. The company also plans to pursue domestic and international clinical research for rheumatoid arthritis, an autoimmune disease. A company official stated, "As the clinical development of Penitrium gains momentum, we expect it to present new possibilities for the treatment of intractable diseases."

Chairman Cho Wondong of Penitrium Bioscience said, "If we understand the pathological environment of intractable diseases from the perspective of cellular energy metabolism, we can discover common therapeutic approaches even among different diseases." He added, "Whether Penitrium can advance as a new therapeutic paradigm will be steadily verified through future clinical studies."

On the same day, the company also published a pocketbook for the general public titled "Stories of Intractable Diseases with Penitrium." This popular science book explains major intractable diseases such as cancer and autoimmune disorders from the perspective of cellular energy metabolism, making it easy to understand the common pathological environments of these diseases. The book, not for sale, will be distributed to academia, the medical community, investors, and general readers.

This content was produced with the assistance of AI translation services.